Use of bisoprolol in heart failure. The BISOCOR observational study;Empleo de bisoprolol en la insuficiencia cardíaca. Resultados del estudio BISOCOR

Revista Espanola de Cardiologia

Volumn 56, Issue 9, 2003, Pages 873-879

  González Juanatey, José R ^a   Alegría Ezquerra, Eduardo ^b   García Saavedra, Vicente ^c   Pérez Ojeda, Germán ^d   Ruiz Ros, José A ^e   Espinosa Caliani, J Salvador ^f   Anguita Sánchez, Manuel ^g  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c Pius Hospital de Valls   (Spain)

^d HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Beta blockers; Bisoprolol; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; HYPOTENSION; INTERMITTENT CLAUDICATION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MEDICAL SOCIETY; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; SINUS BRADYCARDIA; SPAIN; SUDDEN DEATH; SURGICAL TECHNIQUE;

EID: 0242410149     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13051614     Document Type: Article

References (21)

1. Tendera M, Ochala A. Overview of the results of recent beta blocker trials. Curr Opin Cardiol 2001;16:180-5.
2. Pritchett AM, Redfield MM. Beta-blockers: new standard therapy for heart failure. Mayo Clin Proc 2002;77:839-46.
3. Goldstein S. Benefits of beta-blockers therapy for heart failure. Arch Intern Med 2002:162:641-8.
4. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83(Suppl 2A):A1-38.
5. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Eur J Heart Fail 2002;4:11-22.
6. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
7. Gomberg-Maitland M, Baran DA, Fuster V. Treatment of congestive heart failure. Guidelines for the primary care physician and the heart. Arch Intern Med 2001;161:342-52.
8. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
9. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al, for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
10. Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Medicina Interna (SEMI). La insuficiencia cardíaca en los servicios de medicina interna (estudio SEMI-IC). Med Clin (Barc) 2002;118:605-10.
11. Davis M. Bisoprolol in chronic heart failure. Hosp Med 2000;61: 120-3.
12. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-74.
13. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000;84:615-9.
14. CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999;353:9-13.
15. Rector T, Kubo S, Cohn JN. Patients self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure. The Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3:198-209.
16. Ascaso C. Introducción a la estadística médica. En: Rodés J, Guardia J, editores. Medicina interna. Barcelona: Masson, 1997; p. 615-22.
17. Francis GS, Cohn JN, Johnsons G. Plasma norepinephrine, plasma renin activity and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II follow-up. Circulation 1993;87(Suppl VI):40-8.
18. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-8.
19. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
20. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
21. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.